Our Clinical Trials
 

Neurologic conditions

BB-IND 13729 (Orphan Drug designation)

Infusion of ex vivo expanded autologous bone marrow-derived mesenchymal stem cells, in patients with Amyotrophic Lateral Sclerosis.

  • Phase I: Active, Not Recruiting

BB-IND 13981

Transfer of autologous bone marrow-derived mesenchymal stem cell for the treatment of spinal cord injury.

  • Phase I: Active, Not Recruiting

 

Cardiovascular conditions

BB-IND 13562

Transfer of bone marrow-derived mononuclear and mesenchymal stem cells into the myocardium for the treatment of severe coronary ischemia.

  • Phase I: Completed
  • Phase II: Partial Clinical Hold

BB-IND 11643

Repair of infarcted myocardium in patients during bypass surgery and rescue and repair of cardiac muscle after acute myocardial infarction.

  • Phase I: Completed - Partial Clinical Hold

BB-IND 13139

Efficacy of an intra-muscular infusion of a combination cell product to patients with severe limb ischemia.

  • Phase I: Completed
  • Phase II: Completed – Partial Clinical Hold

 

back to the top